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ever, early transplant-related mortality (TRM) was similar in both
groups. Besides both the frequency of acute and chronic GvHD
were not affected by the intensity of conditioning regimen. In
median 24.2 months (0.2-36 ms) of follow-up period, 3-year-
probability of DFS and OS in RIC compared to MA were 34.7 %
vs 46.9 % (log-analysis, p0.31) and 61.2 % vs 47.2 % (p0.37),
respectively. Conclusion: We observed less regimen related tox-
icity in RIC group as expected. Although the incidence of disease
relapse was more frequent in RIC group than MA group, both
DFS and OS were found in similar rates in both regimen. In CML
patients RIC regimen could be preferable instead of a MA regimen,
in high risk transplant candidates. We have still no evidence for
RIC about durable control of CML. After the completion of an
ongoing prospective and randomized phase III study in CML
comparing the RIC with MA in our center; we will extensively
evaluate the impact of RIC at allogeneic transplantation.
Transplantation data
Variables RIC group (n25) p MA group (n48)
Median CD34 (10e6/
BW kg) (range)
4.63 (2.49-13.16) 0.283 4.85 (0.36-18.90)
Median MNC (10e8/
BW kg) (range)
4.31 (0.98-19.15) 0.953 4.79 (0.55-19.15)
Median CD3 (10e8/
BW kg) (range)
21.70 (1.00-100.26) 0.071 25.10 (1.0-294.54)
Median Gratwohl
Score (range)
2 (1-4) 0.795 2 (1-4)
Engraftment
kinetics
Neutrophil>
0.5109/L,
median days
(range)
15 (0-20) 0.699 14 (10-32)
Platelet> 20109/L,
median days
(range)
10 (0-15) <0.0001* 13.5 (8-32)
Mucositis (Present/
Absent)
11/14 <0.0001* 45/3
Median grade of
mucositis (range)
0 (0-3) <0.0001 2 (0-4)
Median days of
mucositis (range)
0 (0-14) <0.0001* 7 (0-20)
Febrile episode
(Present/Absent)
11/14 <0.0001* 45/3
Median incidence of
febrile episode, n
0 (0-2) <0.0001* 1 (0-3)
Median days of
febrile episode
(range)
0 (0-8) 0.008* 2 (0-15)
TPN use 22% <0.0001* 77%
Acute GvHD 34.8% 0.785 29.8%
Chronic GvHD 76.2% 0.504 72.5%
Early transplant-
related mortality
12.0% 0.522 20.8%
Relapse 52% 0.001* 26%
3-year- probability
of DFS
34.67%  10.62% 0.314 46.85%  7.89%
3-year- probability
of OS
61.24%  10.24% 0.367 47,19%  7.85%
*p0.05
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C-REACTIVE PROTEIN (CRP) MAY PREDICT TRANSPLANT-RELATED
MORTALITY AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT
(HCT)
Artz, A.S.1, Wickrema, A.1, Stock, W.1, Daugherty, C.1, Godley, L.1,
Kocherginsky, M.1, Odenike, O.1, Pollyea, D.1, Rich, E.1, Ulsazek, J.1,
Larson, R.1, van Besien, K.1 1University of Chicago Pritzerk School of
Medicine, Chicago, IL.
Current prognostic factors for transplant related mortality
(TRM) are disease status, the presence of comorbid conditions, and
performance status. Each of these measures has problems of sen-
sitivity and discriminative capacity. CRP, a marker of systemic
inﬂammation, has shown considerable value in non-HCT setting
to predict vascular events and overall survival(OS). We hypothe-
sized that elevated CRP would predict for worse HCT outcome.
Using a highly sensitive CRP assay, pre-HCT CRP levels were
analyzed in 41 consecutive patients with MDS or AML who un-
derwent HCT after a preparative regimen of ﬂudarabine (125
mg/m2 IV total), melphalan (140 mg/m2 IV total) and alemtu-
zumab (100 mg IV total). The median age was 52 years and 11/41
had active had active disease at HCT. The median CRP level was
20.6 mg/L and the mean was 38.5 mg/L (range 0.3 to 180). Six
month TRM was 23% with a median follow-up for survivors of 15
months. There was a signiﬁcant association between higher pre-
HCT CRP levels and TRM (P 0.03). CRP levels above the
median had a hazard ratio of 3.2 (P  0.07). CRP also showed an
association with overall survival (OS) (P 0.07) of borderline
statistical signiﬁcance. CRP remained predictive of TRM after
adjusting for disease status (P  0.06), charlson comorbidity index
(P  0.03), kaplan-feinstein comorbidity index (P  0.01), ECOG
performance status (P0.07) and age over 50 (P0.04). We con-
clude that in HCT recipients, the independent prognostic value of
CRP for TRM suggests the potential to enhance estimates of HCT
outcome in addition to standard prognostic factors. Prospective
studies in larger patient cohorts should be pursued to conﬁrm the
independent value of CRP and other pro-inﬂammatory cytokines
on HCT outcome.
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THIOTEPA BASED CONDITIONING REGIMEN IN 374 PATIENTS UNDER-
GOING ALLOGENEIC STEM CELL TRANSPLANTS FROM RELATED OR
UNRELATED DONORS
Bacigalupo, A.1, Gualandi, F.1, Occhini, D.1, Bregante, S.1,
Lamparelli, T.1, Raiola, A.M.1, Ibatici, A.1, Di Grazia, C.1,
Dominietto, A.1, Bruno, B.1, van Lint, M.T.1, Frassoni, F.1 1Hematol-
ogy Division, S.Martino’s Hospital, Genova, Italy.
Background:The Perugia group introduced thiotepa (THIO) in
allogeneic stem cell transplants (HSCT): we have developed
THIO based conditioning regimens in combination with cyclo-
phopshamide (CY), Fludarabine (FLU), melphalan (MEL) or TBI
200 mainly for patients above the age 45.
Aim of the study: assess the outcome of patients undergoing an
allogeneic HSCT with a THIO based conditioning regimen.
Patients. 374 patients were allografted with a THIO based
regimen, between 1994 and 2005, from HLA identical siblings
(SIB) (n221) or family partially mismatched (n67) or unrelated
(n86) donors. Median patient age was 48 years (range16-.67).
The stem cell source was unmanipulated in all cases , either bone
marrow (n276) or peripheral blood (n98). The conditioniong
regimens were classiﬁed as reduced intensity (n177) (THIO-CY
or THIO-FLU) or intensiﬁed (n197) (THIOCY supple-
mented with MEL or TBI). The disease was in 1stCR (n221) or
more advanced phase (n153). Patients had chronic myeloprolif-
erative disorders (n123), acute leukemia (n120), myelodisplasia
(n46), other (n85, including lymphoma and myeloma). All,
patients received cyclosporin methotrexate GvHD prophylaxis;
anti-thymocyte globulin was added for alternative donor trans-
plants. The median follow up for surviving patients is 5 years
(range 1-12 years)
Results: The overall actuarial 10 year survival is 40%, (60% vs
30% in CR1 or CR1 disease). The cumulative incidence (CI) of
transplant related mortality (TRM) at 10 years is 29% (18% vs 36%
for CR1 or CR1 disease); TRM for CR1 patients grafted from
identical siblings (n94) is 12%. Acute GvHD grade III-IV was
seen in 6% of sibling HSCT and 12% of alternative donor grafts.
The CI of relapse related death (RRD) at 10 years was 27% (18% vs
32% in CR1 or CR1). There was no effect of patient age, nor of
stem cell source on survival. In multivariate analysis on survival,
signiﬁcant predictors were disease phase (RR 2.4 of death for
patients beyond CR1) and intensity of the conditioning (RR 1.66
for intensiﬁed regimens); these two variables also predicted TRM;
disease phase predicted RRD.
Conclusions: This study shows that THIO based conditioning
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